Medical condition
Metastatic Pancreatic Cancer
Metastatic Pancreatic Cancer is a medical condition tracked by NovaPharmaNews across 2 associated drugs and ongoing industry coverage. Explore approved and pipeline therapies, regulatory status, and the latest developments.
Associated drugs & therapies
- erlotinib (ERLOTINIB ARX) Antineoplastic and immunomodulating agents (L01)
- masitinib (MASITINIB AB SCIENCE) Antineoplastic and immunomodulating agents (L01)
Latest Metastatic Pancreatic Cancer news
First RAS Inhibitor Extends Survival in Metastatic Pancreatic Cancer
Daraxonrasib, the first RAS inhibitor, has received FDA approval, extending survival in metastatic pancreatic adenocarcinoma. This article outlines key updates and implications for stakeholders.
Phanes Therapeutics to Present Updated Spevatamig Phase 2 Results for Metastatic Pancreatic Cancer at ASCO 2026
Phanes Therapeutics will present updated Phase 2 clinical trial results of spevatamig (PT886) combined with chemotherapy for metastatic pancreatic cancer treatment.